Neurescue wins CE mark for cardiac arrest treatment device
September 9, 2025
Neurescue announced today that it received CE mark approval for its device designed to treat non-shockable cardiac arrest.
Neurescue announced today that it received CE mark approval for its device designed to treat non-shockable cardiac arrest.
Stryker (NYSE: SYK)+
today announced the launch of its recently FDA-cleared Incompass total ankle system.
Varian announced its Embozene microspheres have received CE mark for genicular artery embolisation (GAE) to treat knee osteoarthritis.
The FDA’s clearance of LIBERTY follows the completion of Microbot’s pivotal trial in April 2025, achieving a 100% success rate in robotic navigation.
ARC‑EX is the first system to receive a CE Mark in Europe specifically for improving hand and arm strength and sensation in adults with chronic, incomplete spinal cord injury.
Researchers have developed a material that can sense tiny changes within the body, such as during an arthritis flareup, and release drugs exactly where and when they are needed.
Physicians rely on nuclear medicine scans, like SPECT scans, to watch the heart pump, track blood flow and detect diseases hidden deep inside the body. But today’s scanners depend on expensive detectors that are difficult to make.
Indiana University School of Medicine scientists have developed a new method that shifts the behavior of immunosuppressive cells in tumors, turning them from cancer protectors into tumor fighters.
Suicide is a leading cause of death in postpartum women—and it is a preventable one. It is estimated that nearly half of mothers experiencing perinatal depression are undiagnosed and are not receiving treatment. But when women are given vital mental health tools in an accessible manner, their deaths can be prevented.
Researchers have harnessed the power of artificial intelligence to tackle one of the most complex challenges in immunology: predicting how T cells recognize and respond to specific peptide antigens.